Sex: U
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Interchange of vaccine products
Clinical narrative: COVID-19/very bad taste in mouth; Interchange of vaccine products; This spontaneous case was reported by a non-health professional and describes the occurrence of COVID-19 (COVID-19/very bad taste in mouth) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036B21A and 030A21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    Patient did not had history of concurrent conditions.  Concurrent medical conditions included Allergy NOS.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Dec-2021, the patient received third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 06-May-2022 at 3:00 PM, received fourth dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19/very bad taste in mouth) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 07-May-2022 to 09-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19/very bad taste in mouth) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.            Concomitant medications were not reported.  It was stated that the patient did not took any other medications/products within 2 weeks of starting COVID-19 treatment.  No treatment medication given for the treatment of very bad taste in mouth also had rebound infection.  Company comment: This spontaneous case concerns a patient of an unknown age and gender with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, that occurred approximately 1 year and 25 days after receiving the second dose of mRNA-1273 given. Patient was treated with a 3-day-course of Nirmatrelvir, Ritonavir (Paxlovid) for COVID-19 infection and presented with rebound COVID-19.  No COVID-tests were reported before and after Paxlovid treatment.  First dose of mRNA-1273 was given 28 days prior to current mRNA-1273. Patient also received 2 doses of non-company brand COVID-19 vaccination TOZINAMERAN (PFIZER BIONTECH) given as third and fourth dose. Interchange of vaccine products was noted. The benefit-risk relationship of mRNA-1273 is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a patient of an unknown age and gender with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, that occurred approximately 1 year and 25 days after receiving the second dose of mRNA-1273 given. Patient was treated with a 3-day-course of Nirmatrelvir, Ritonavir (Paxlovid) for COVID-19 infection and presented with rebound COVID-19.  No COVID-tests were reported before and after Paxlovid treatment.  First dose of mRNA-1273 was given 28 days prior to current mRNA-1273. Patient also received 2 doses of non-company brand COVID-19 vaccination TOZINAMERAN (PFIZER BIONTECH) given as third and fourth dose. Interchange of vaccine products was noted.. The benefit-risk relationship of mRNA-1273 is not affected by this report.